The document provides an overview of Zynex, Inc., a medical device manufacturer. It notes that statements and estimates in the presentation involve risks and uncertainties. It summarizes Zynex's business units, products, financial performance, growth objectives, and management team. The purpose is to provide investors with information about Zynex while cautioning that actual results may differ from estimates.

2. Forward Looking Statements
Statements made in this presentation include financial estimates and forward-looking
statements that are not historical facts. Each of these estimates and forward-looking
statements involves risk and uncertainties. These estimates are based on present
circumstances, information currently available, and assumptions about future
revenues, industry growth, and general economic conditions. Estimates are inherently
uncertain as they are based on assumptions concerning future events. No
representations can be made as to the accuracy of such information or the reliability
of such assumptions. Accordingly, actual revenues and expenditures may vary
significantly from the Company’s estimates, and actual results or developments may
differ materially from those expressed or implied by the forward-looking
statements. Factors that could cause actual results to differ from the financial
estimates and forward-looking statements in this presentation include those
described in the Company’s filings with the Securities and Exchange Commission,
including the “Risk Factors” section of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2014, as updated in 2015 quarter periods.
Therefore, neither the Company’s estimates nor the assumptions upon which they
are based are to be interpreted as a guarantee or promise of the Company or
management. The Company has no obligation to modify, amend, update, alter, or
change the estimates contained herein.
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com
Dec 2015 2OTCQB: ZYXI

3. Zynex Overview
• Medical Device Manufacturer
o Non-invasive, conservative pain treatment
o Neuro-Monitoring, Stroke Recovery
o Blood volume monitoring
• Publicly Traded OTCQB: ZYXI
• In operation since 1996, headquartered in Lone Tree, Colorado
• >60%+ recurring revenue with more than 280,000 patients treated since
inception
• High Gross Profit Margin of >70%
• Estimated $3b market potential
Dec 2015 3OTCQB: ZYXI

4. Business Structure
Zynex, Inc.
Zynex Medical
Inc.
Electrotherapy
Neurodiagnostics
Inc.
EMG & EEG
Monitoring
NeuroMove
Stroke rehab
Monitoring
Solutions
Blood Volume
Monitor (R&D)
Dec 2015 4OTCQB: ZYXI

5. Business Unit Summary
• ZYNEX MEDICAL (ZMI)
o Non-invasive electrotherapy pain management devices “TENS” (90% of
historical revenue)
• RX required, insurance billed
• >70% GPM, >60% recurring revenue (consumable supplies and
rentals)
• ZYNEX NEURODIAGNOSTICS (ZND)
o EEG EMG diagnostics B:B products (2% of historical revenue)
o NeuroMove Stroke Rehab product
• ZYNEX MONITORING SOLUTIONS (ZMS)
o In development, non-invasive blood volume monitor (Zero revenue)
Dec 2015 5OTCQB: ZYXI

6. Products – Zynex Medical
• Complete line of electrotherapy pain
management devices-FDA cleared and CE
marked
• Augments healing, alleviates swelling through
increased blood circulation, and reduces both
acute/chronic pain through the use of
electrical currents
• Requires a prescription
• Requires Consumables
• Reimbursed by health insurance
• May be rented or purchased
• $500 million industry worldwide
Dec 2015 6
NexWave
Consumables (battery/electrode)
OTCQB: ZYXI

7. Products – Zynex Medical
• Stroke/spinal cord rehabilitation
devices-FDA cleared and CE
marked
• Augment healing, as well as
assist in recovery for stroke,
Spinal Cord Injuries and
Traumatic Brain Injury, retrains
muscles, increases range of
motion
• Consumables required
Dec 2015 7
NeuroMove
Consumables (electrodes)
OTCQB: ZYXI

8. Products – Monitoring Solutions
• CM1500 – non invasive blood
volume monitor
• Used in operating and recovery
rooms to detect blood loss and
internal bleeding
• FDA 510(k) application submitted in
Sept. 2015. Ongoing clinical
evaluation underway
• Patent filed
• $3b market potential
Dec 2015 8
Blood Volume Monitor
(in development)
OTCQB: ZYXI

9. Revenue Growth
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
40000000
45000000
'04 '05 '06 '07 '08 '09 '10 11 12 13 14 15
9 months
ended
09/30/15
Dec 2015 9OTCQB: ZYXI

10. Financial Summary
Dec 2015 10OTCQB: ZYXI
All figures in $1,000’s 9 months ended
9/30/2015
2014 2013 2012 2011 2010 2009 2008 2007
Revenue 8,923 11,117 21,684 39,666 34,148 24,085 18,681 11,764 8,048
Gross Profit 5,562 3,505 13,544 30,896 26,777 18,883 14,888 9,524 7,319
Net Income -1,711 -6,199 -7,301 1,553 1,564 350 2,382 111 2,132
Cash 41 63 323 823 789 602 863 - -
EPS -0.05 -0.20 -0.23 0.05 0.05 0.01 0.08 0 0.07
Cash Flow From
Operations
82 961 -382 -879 -362 -665 3,648 -715 746
Stockholders' Equity -2,845 -1,201 4,882 12,050 10,140 8,182 7,486 4,774 3,617
Common Shares
Outstanding
31,271 31,208 31,171 31,148 30,800 30,600 30,500 29,900 26,800

11. Balance Sheet
Dec 2015 11OTCQB: ZYXI
9 months ended
Sept. 30, 2015 2014 2013 2012 2011
Cash: 41 63 323 823 789
A/R: 2,776 3,189 7,033 12,224 10,984
Inventory: 1,110 1,935 5,002 6,160 4,557
Other Assets: 40 518 1,346 2,155 1,718
Current Assets: 3,967 5,705 13,704 21,362 18,048
Property,P&E: 874 1,276 2,891 3,851 3,422
Other Assets: 139 133 626 723 315
Total Assets: 4,890 7,114 17,221 25,936 21,785
Line of Credit: 4,322 4,442 5,820 5,906 3,290
Other Liabilities: 3,319 3,615 3,864 6,187 6,460
Current Liabilities: 7,641 8,057 9,684 12,093 9,750
Other Liabilities: 268 324 2,689 1,788 1,896
Total Liabilities: 7,909 8,381 12,373 13,881 11,646
Common Stock: 31 31 31 31 31
Paid-in-capital: 5,769 5,702 5,586 5,453 5,095
Retained earnings: -8,645 -6,934 -735 6,566 5,013
Non-control int: -84 -66 -34 5 -
Total Stockh eq: -2,929 -1,267 4,848 12,055 10,139
Total Liability &
Stockholder Eq: 4,980 7,114 17,221 25,936 21,785

12. Available Market
Dec 2015 12OTCQB: ZYXI
AVAILABLE MARKET ~$3.7B
ZYNEX MEDICAL
Electrotherapy Devices $500M
ZYNEX MONITORING SOLUTIONS
Cardiac Monitoring Devices $3B
ZYNEX NEURODIAGNOSTICS
Biofeedback/Rehab $220M
Market size based on internal management estimates and various market sources

13. Current Business Factors
• Zynex Medical – Electrotherapy TENS
• TENS business impacted in 2013 due to Affordable Healthcare Act
implementation & reimbursement changes
• TENS business stabilized in 2014, and begins to grow in 2015
o EMPI announced exit from TENS market in November 2015
• Zynex develops strategies to service EMPI customers & recruit top
tier EMPI sales reps
• Zynex Monitoring Solutions - CM1500
o Sept 2015 – FDA 510(k) application filed for clearance of CM1500
monitoring device.
o The CM1500 is capable of monitoring a patient's fluid levels, including
blood loss, during surgery and in recovery.
Dec 2015 13OTCQB: ZYXI

14. Long Term Objectives
• Listing on NYSE MKT or NASDAQ
• Grow recurring revenue streams
• Generate consistent net earnings and positive free
cash flow
• Reinvest to develop devices and applications with
high GPM
• Focus on driving value thru organic growth and
strategic acquisitions
Dec 2015 14OTCQB: ZYXI

15. Corporate & Ownership Structure
Dec 2015 15
Common Stock: 31,271,234 shares outstanding
OTCBB: ZYXI
Auditors: GHP Horwath
Counsel: Burns, Figa and Will
OTCQB: ZYXI

16. Major Milestones
1996
• Founded by Thomas Sandgaard
1999
• FDA clearance on first Zynex E-Stim device
2001
• Shifted from wholesale to direct sales to physicians and patients
2004
• Reverse merger into a public entity
2008
• Received European CE mark on key products
2010
• Established NeuroDiagnostics (EEG/Sleep) and Monitoring (blood volume) subsidiaries
2011
• Commenced clinical evaluations for Blood Volume Monitor device
2013
• Impacted by Health Care Reform – restructured core business
2015
• TENS business begins to grow. EMPI (largest competitor) exits TENS market in November
Dec 2015 16OTCQB: ZYXI

17. Management Team Bio
Thomas Sandgaard has been the Chairman of the Board, President and Chief
Executive Officer of Zynex, Inc. since founding the company in 1996. He has
previously held management positions with companies such as ITT, Siemens, GN
Danavox, Dataco and Philips. Most of his work has been in the areas of international
sales and distribution, technology transfers, mergers and marketing management in
the semiconductor, telecommunications, data communications and medical
equipment industries. Mr. Sandgaard has a bachelor’s degree in electronics
engineering from University of Southern Denmark and an MBA from Copenhagen
Business School. Mr. Sandgaard has an in-depth knowledge of the industry and is the
driving force as to the Company strategies.
Paul Oberman, has been interim Chief Financial Officer of Zynex, Inc. since October
2015. Mr. Oberman is a founder and partner of C Squared Solutions, LLC with over
40 years of executive leadership and management experience. Prior to joining C
Squared, Mr. Oberman has served as Chief Financial Officer for Great American, LLC
and MDC Holdings, Inc. Mr. Oberman is an alumnus of Deloitte & Touche and KPMG
and has a MBA and BBA from the University of Michigan
Dec 2015 17OTCQB: ZYXI

18. Contact Information
For more information, please contact:
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153
www.zynex.com
Dec 2015 18OTCQB: ZYXI

19. Stock Symbol
ZYXI
Dec 2015 19OTCQB: ZYXI